Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High Copaxone Dose Fails To Show Superiority In MS, Teva Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In Phase III, 40 mg dose did not reduce relapse rate in patients over the approved 20 mg strength.

You may also be interested in...



Following Phase II Failure, Teva Drops Investigation Of Glatiramer For ALS

Compound fails to meet primary and secondary trial endpoints.

Teva Plans Copaxone sNDA For Earlier Use In MS Patients After First Clinical Event

Filing is based on interim analysis of a trial showing glatiramer reduced risk of developing clinically definite multiple sclerosis.

Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data

Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.

Related Content

Topics

UsernamePublicRestriction

Register

PS068181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel